HRP20110253T1 - Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze - Google Patents

Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze Download PDF

Info

Publication number
HRP20110253T1
HRP20110253T1 HR20110253T HRP20110253T HRP20110253T1 HR P20110253 T1 HRP20110253 T1 HR P20110253T1 HR 20110253 T HR20110253 T HR 20110253T HR P20110253 T HRP20110253 T HR P20110253T HR P20110253 T1 HRP20110253 T1 HR P20110253T1
Authority
HR
Croatia
Prior art keywords
inhibitors
antagonists
agonists
compound according
compound
Prior art date
Application number
HR20110253T
Other languages
English (en)
Croatian (hr)
Inventor
Manuel Vieira Ara�jo Soares Da Silva Patr�cio
Alexander Learmonth David
Beliaev Alexander
Original Assignee
Bial-Portela & Ca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38198874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110253(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bial-Portela & Ca filed Critical Bial-Portela & Ca
Publication of HRP20110253T1 publication Critical patent/HRP20110253T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20110253T 2007-05-08 2008-05-06 Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze HRP20110253T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0708818.0A GB0708818D0 (en) 2007-05-08 2007-05-08 Compounds
PCT/PT2008/000019 WO2008136695A1 (en) 2007-05-08 2008-05-06 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase

Publications (1)

Publication Number Publication Date
HRP20110253T1 true HRP20110253T1 (hr) 2011-05-31

Family

ID=38198874

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110253T HRP20110253T1 (hr) 2007-05-08 2008-05-06 Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze

Country Status (29)

Country Link
US (5) US8481582B2 (OSRAM)
EP (1) EP2155731B1 (OSRAM)
JP (1) JP5559677B2 (OSRAM)
KR (1) KR101598482B1 (OSRAM)
CN (1) CN101687858B (OSRAM)
AR (2) AR066457A1 (OSRAM)
AT (1) ATE499367T1 (OSRAM)
AU (1) AU2008246443B2 (OSRAM)
BR (1) BRPI0811275B8 (OSRAM)
CA (1) CA2686387C (OSRAM)
CL (1) CL2008001321A1 (OSRAM)
CY (1) CY1111517T1 (OSRAM)
DE (1) DE602008005141D1 (OSRAM)
DK (1) DK2155731T3 (OSRAM)
ES (1) ES2360841T3 (OSRAM)
GB (1) GB0708818D0 (OSRAM)
HR (1) HRP20110253T1 (OSRAM)
IL (1) IL201921A (OSRAM)
MX (1) MX2009012041A (OSRAM)
NO (1) NO20093275L (OSRAM)
NZ (1) NZ580962A (OSRAM)
PL (1) PL2155731T3 (OSRAM)
RS (1) RS51692B (OSRAM)
RU (1) RU2501796C2 (OSRAM)
SI (1) SI2155731T1 (OSRAM)
TW (1) TWI458722B (OSRAM)
UA (1) UA104844C2 (OSRAM)
WO (1) WO2008136695A1 (OSRAM)
ZA (1) ZA200908612B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
WO2012020742A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
RU2604734C2 (ru) * 2010-12-22 2016-12-10 БИАЛ-ПОРТЕЛА энд КА., С.А. Кристаллическая форма и способ ее очистки
WO2013002660A2 (en) * 2011-06-29 2013-01-03 BIAL - PORTELA & Cª, S.A. Process
KR102259938B1 (ko) * 2012-11-14 2021-06-03 바이알 - 포르텔라 앤드 씨에이 에스에이 폐동맥 고혈압 및 폐 손상의 치료에 이용하기 위한 1,3-디히드로이미다졸-2-티온 유도체
CN103356671B (zh) * 2013-06-24 2015-11-25 顾祥茂 Houttuynoid C在制备治疗或预防慢性心衰的药物中的应用
GB201316410D0 (en) 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
JOP20190049A1 (ar) * 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
CA3075669A1 (en) 2017-09-13 2019-03-21 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
EP3720856A1 (en) 2017-12-04 2020-10-14 BIAL - PORTELA & Cª, S.A. Dopamine-& x392;-hydroxylase inhibitors
GB201810395D0 (en) 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
SG11202104423XA (en) * 2018-11-12 2021-05-28 Immunogen Inc Methods of preparing cytotoxic benzodiazepine derivatives
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors
US20250134870A1 (en) * 2021-01-26 2025-05-01 Jiangsu Yahong Meditech Co., Ltd. Pathway modulator, pharmaceutical composition having same, use thereof, and therapeutic method using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
BR9507517A (pt) * 1994-04-26 1997-09-16 Syntex Inc Derivados de benzocicloalquilazotetiona
AR032711A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
GB2393958A (en) * 2002-10-11 2004-04-14 Portela & Ca Sa Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds

Also Published As

Publication number Publication date
CN101687858A (zh) 2010-03-31
ZA200908612B (en) 2010-11-24
RS51692B (sr) 2011-10-31
EP2155731A1 (en) 2010-02-24
US9630951B2 (en) 2017-04-25
ATE499367T1 (de) 2011-03-15
EP2155731B1 (en) 2011-02-23
US20170369478A1 (en) 2017-12-28
IL201921A0 (en) 2010-06-16
RU2501796C2 (ru) 2013-12-20
JP5559677B2 (ja) 2014-07-23
US20190322648A1 (en) 2019-10-24
PL2155731T3 (pl) 2011-07-29
IL201921A (en) 2013-11-28
CL2008001321A1 (es) 2008-12-26
SI2155731T1 (sl) 2011-05-31
CA2686387C (en) 2015-06-30
KR20100017546A (ko) 2010-02-16
TW200918525A (en) 2009-05-01
HK1142898A1 (en) 2010-12-17
US20210261533A1 (en) 2021-08-26
AU2008246443A8 (en) 2010-01-07
GB0708818D0 (en) 2007-06-13
ES2360841T3 (es) 2011-06-09
MX2009012041A (es) 2010-02-18
TWI458722B (zh) 2014-11-01
WO2008136695A1 (en) 2008-11-13
BRPI0811275A2 (pt) 2014-12-23
DE602008005141D1 (de) 2011-04-07
BRPI0811275B8 (pt) 2021-05-25
NO20093275L (no) 2010-02-04
AR066457A1 (es) 2009-08-19
NZ580962A (en) 2012-05-25
KR101598482B1 (ko) 2016-02-29
DK2155731T3 (da) 2011-05-02
AR112789A2 (es) 2019-12-11
CY1111517T1 (el) 2015-08-05
US20130345275A1 (en) 2013-12-26
RU2009145270A (ru) 2011-06-20
US20100137390A1 (en) 2010-06-03
UA104844C2 (uk) 2014-03-25
AU2008246443B2 (en) 2013-07-11
US8481582B2 (en) 2013-07-09
CA2686387A1 (en) 2008-11-13
JP2010526136A (ja) 2010-07-29
BRPI0811275B1 (pt) 2020-01-07
CN101687858B (zh) 2012-12-26
AU2008246443A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
HRP20110253T1 (hr) Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze
JP2010526136A5 (OSRAM)
AU2020390962B2 (en) Pyrimidoimidazole compounds used as DNA-PK inhibitors
JP7252972B2 (ja) ３－ヒドロキシ－Ｎ－（３－（７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）フェニル）ピロリジン－１－カルボキサミド誘導体
KR101500766B1 (ko) 치환된 3-이소부틸-9,10-디메톡시-1,3,4,6,7,11ｂ-헥사히드로-2Ｈ-피리도[2,1-ａ]이소퀴놀린-2-올 화합물 및 그와 관련된 방법
US11008302B2 (en) Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
RU2009132881A (ru) Производные пуринила и их применение в качестве модуляторов калиевых каналов
EA201170061A1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
EP3464281A1 (en) Mutant idh1 inhibitors
Song et al. Design and synthesis of 8-substituted benzamido-phenylxanthine derivatives as MAO-B inhibitors
UA102693C2 (ru) Производные фенилимидазола как ингибиторы фермента pde10a
AU2018225312A1 (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
Clark et al. Discovery and SAR development of 2-(phenylamino) imidazolines as postacyclin receptor antagonists
Vangveravong et al. Synthesis of N-substituted 9-azabicyclo [3.3. 1] nonan-3α-yl carbamate analogs as σ2 receptor ligands
US9867826B2 (en) Heterocycles as modulators of kinase activity
Herp et al. First fluorescent acetylspermidine deacetylation assay for HDAC10 identifies selective inhibitors with cellular target engagement
TW201718475A (zh) 尿素衍生物及其用途
MX2010001229A (es) Procedimiento para la resolucion de zopiclona y compuestos intermedios.
Wang et al. A new facile synthetic route to [11C] GSK189254, a selective PET radioligand for imaging of CNS histamine H3 receptor
Fabio et al. Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging
EP3894410A1 (en) Substituted xanthine derivatives
RS64040B1 (sr) Derivat pirimidin sulfamida i njegov postupak dobijanja i primena u medicini
WO2018108954A1 (en) Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
RS65239B1 (sr) Derivati 4-fluoro-1h-pirazolo[3,4-c]piridina kao selektivni inhibitori brutonove tirozin kinaze (btk) za lečenje b-ćelijskih limfoma i autoimunih bolesti